Cures Within Reach

03/17/2026

During Awareness Month, we are proud to now be funding an ongoing Phase IIA trial “Treating with Stellate Ganglion Block via TMS Neuromodulation” led by Dr. Yosef Berlow at Providence VA Medical Center and Ocean State Research Institute.
VA Providence Healthcare System

There is an urgent need for new therapeutic approaches to treating patients with PTSD, as current treatment options often fail to alleviate symptoms for many. This Phase IIA, multi-arm, placebo-controlled trial is testing a neuromodulation method, applying a transcranial magnetic stimulation (TMS) d...

03/13/2026

Apply for clinical trial funding! Our 2026 LMIC, Chicago and Veterans RFPs are open for submissions. Read about these and our 6 recently selected AI Validation clinical trials plus meet our March Researcher Spotlight: Dr. Lixin Zhang of Dent Neurologic Institute in our March newsletter: https://bit.ly/3Nmqbm9

03/05/2026

Clinical trial funding available for : apply by April 10 to our open RFP. We will fund up to 9 clinical trials testing off-patent, approved therapies led by under-resourced researchers and clinicians in . Budgets of up to US$70,000 and a preference for impacting high disease burden. More details at https://bit.ly/cwrrfps. Help spread the word!

02/28/2026

On , we celebrate patients and caregivers. Our selection of 6 new clinical trials to validate AI-driven drug-disease predictions, including 3 trials focused on rare/ultra-rare diseases, represents a pivotal step in turning powerful computational predictions into real treatments for patients. By combining AI insights with real-world clinical validation, these trials aim to accelerate access to therapies and bring new hope to patients who have long had none. Because in rare diseases, speed matters.

https://www.cureswithinreach.org/2026/02/25/press-release-cures-within-reach-selected-three-clinical-trials-in-rare-ultrarare/

Biohub Channeling Hope Foundation Jeremy Tanner Tyler Beck National Center for Advancing Translational Sciences Lyda Hill Philanthropies Nicole Small National Organization for Rare Disorders, Inc. (NORD) Global Genes EURORDIS-Rare Diseases Europe Canadian Organization for Rare Disorders Rare Disease Day

02/25/2026

Ahead of Rare Disease Day, we’re taking an important step forward for the community. We have selected 6 new clinical trials to validate AI-driven drug-disease predictions, including 3 trials focused on rare/ultra-rare diseases, which represents a pivotal step in turning powerful computational predictions into real treatments for patients. By combining AI insights with real-world clinical validation, these trials aim to accelerate access to therapies and bring new hope to patients who have long had none. Because in rare diseases, speed matters.

https://www.cureswithinreach.org/2026/02/25/press-release-cures-within-reach-selected-three-clinical-trials-in-rare-ultrarare/
Biohub
Channeling Hope Foundation
Jeremy Tanner
Tyler Beck
National Center for Advancing Translational Sciences
Lyda Hill Philanthropies
Nicole Small

02/19/2026

Our funding is now supporting an ongoing Phase II trial led by Dr. Chinwe Chukwudi at University of of Nigeria: Treating Cutaneous Leishmaniasis with a Topical Antiseptic in Nigeria. Read more here: https://www.cureswithinreach.org/2026/01/26/treating-cutaneous-leishmaniasis-with-a-topical-antiseptic-in-nigeria/

Leishmaniasis is a neglected tropical disease caused by parasites transmitted through sandfly bites, affecting 1 to 2 million people and leading to thousands of deaths each year. Treatment remains a challenge worldwide due to variability of parasite species across regions and limited efficacy/access...

02/17/2026

Spread the word about our clinical trial funding! Our 2026 LMIC and Chicago-focused RFPs are now accepting LOI submissions. Read about these and other RFPs coming soon plus meet our Feb Researcher Spotlight: Dr. Austin Wesevich of The University of Chicago in our Feb newsletter: https://bit.ly/4cw4uu3​​

02/11/2026

Exciting News! We selected 7 new LMIC-based clinical repurposing trials in 2025 to advance therapies for patients facing high disease burdens using generic, available medicines. With support from Coefficient Giving, these trials are led by researchers in Bangladesh, India, Kenya, Nigeria and Tanzania plus funding for engaging community organizations. This brings our LMIC portfolio to 26 trials with more to be selected in 2026 from our now open funding opportunity RFP, all to strengthen local research capacity and accelerating equitable access to treatment. Learn more: https://www.cureswithinreach.org/2026/02/11/press-release-cwr-selected-seven-more-clinical-trials-to-address-factors-that-lead-to-high-disease-burden-in-low-and-lower-middle-income-countries/

01/30/2026

Our 2025 Annual Report is live: celebrating 20 years, $17mil in catalytic follow-on funding and 16 trials started. Help spread the word bit.ly/CWRAR25. Together, we are turning existing medicines into new possibilities for patients in need.

01/20/2026

Our funding is now supporting this already ongoing led by Dr. Jackton Omoto at Maseno university: Improving Pre-Cancerous Lesion Treatment Among HIV-Positive Women in Kenya - our 11th in women’s health. Read more: www.cureswithinreach.org/2025/12/10/i...

01/16/2026

A record 145 volunteer grant reviewers helped us select 17 trials in 2025. Read more and meet our Jan Researcher Spotlight: Dr. Fahafahantsoa Rapelanoro Rabenja of University of Antananarivo in our Jan newsletter: https://bit.ly/3LwneyI

12/12/2025

Our funding is now supporting an ongoing Phase II trial led by Dr. Olufemi Idowu at Lagos State University: Helping Recovery After Traumatic Brain Injury with Vitamin D3 in Nigeria. Read more here: https://www.cureswithinreach.org/2025/11/11/helping-recovery-after-traumatic-brain-injury-with-vitamin-d3-in-nigeria/